Advertisement
Home »

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.

Apr 24, 2023

REFERENCES & ADDITIONAL READING

PubMed

ABOUT THE EXPERTS

  • Yonghong Li

    Quest Diagnostics, San Juan Capistrano, CA, USA.

    Jose Solis-Ruiz

    Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

    Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

    Fei Yang

    Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

    Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

    Nicola Long

    Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

    Carmen H Tong

    Quest Diagnostics, San Juan Capistrano, CA, USA.

    Felicitas L Lacbawan

    Quest Diagnostics, San Juan Capistrano, CA, USA.

    Frederick K Racke

    Quest Diagnostics, San Juan Capistrano, CA, USA.

    Richard D Press

    Department of Pathology, Oregon Health & Science University, Portland, OR, USA. pressr@ohsu.edu.

    Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. pressr@ohsu.edu.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement